Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

References 79

1. 1.

   Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):1-18.

   Not in our library10.1038/nature22071

2. 2.

   Opdualag summary of product characteristics.

   Not in our library

3. 3.

   Ewen T, Husain A, Stefanos N, et al. Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma. Br J Dermatol. 2024;190(4):549-558.

   Not in our library10.1093/bjd/ljad459

4. 4.

   Marchetti MA, Coit DG, Dusza SW, et al. Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(9):953-962.

   Not in our library10.1001/jamadermatol.2020.1731

5. 5.

   Meyer S, Fuchs TJ, Bosserhoff AK, et al. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One. 2012;7(6):e38222.

   Not in our library10.1371/journal.pone.0038222

6. 6.

   Amaral T, Sinnberg T, Chatziioannou E, et al. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer. 2023;182:155-162.

   Not in our library10.1016/j.ejca.2022.12.021

7. 7.

   Kashani-Sabet M, Leachman SA, Stein JA, et al. Early detection and prognostic assessment of cutaneous melanoma: consensus on optimal practice and the role of gene expression profile testing. JAMA Dermatol. 2023;159(5):545-553.

   Not in our library10.1001/jamadermatol.2023.0127

8. 8.

   Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. Lancet. 2023;402(10400):485-502.

   Not in our library10.1016/s0140-6736(23)00821-8

9. 9.

   Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med. 1977;297(12):627-630.

   Not in our library10.1056/nejm197709222971202

10. 10.

    Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer. 1978;41(3):948-956.

    Not in our library10.1002/1097-0142(197803)41:3<948::aid-cncr2820410324>3.0.co;2-z

11. 11.

    Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224(3):255-263.

    Not in our library10.1097/00000658-199609000-00002

12. 12.

    Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351(9105):793-796.

    Not in our library10.1016/s0140-6736(97)08260-3

13. 13.

    Gershenwald JE, Scolyer RA, Hess KR, Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 2017;563-586.

    Not in our library

14. 14.

    Garbe C, Keim U, Amaral T, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol. 2022;40(32):3741-3749.

    Not in our library10.1200/jco.22.00202

15. 15.

    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.

    Not in our library10.3322/caac.21409

16. 16.

    Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol. 2024;42(14):1619-1624.

    Not in our library10.1200/jco.23.02355

17. 17.

    Kirkwood JM, Weber J, Hoeller C, et al. Adjuvant nivolumab versus placebo in resected stage IIB/C melanoma: update on CheckMate 76K. 2023.

    Not in our library

18. 18.

    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.

    Not in our library10.1200/jco.2009.23.4799

19. 19.

    Amaral T, Nanz L, Stadler R, et al. Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB. Eur J Cancer. 2024;201:113912.

    Not in our library10.1016/j.ejca.2024.113912

20. 20.

    Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517-527.

    Not in our library10.1200/jco.22.00533

21. 21.

    Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845-1855.

    Not in our library10.1056/nejmoa1611299

22. 22.

    Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29(17):3352-3361.

    Not in our library10.1158/1078-0432.ccr-22-3145

23. 23.

    Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824-1835.

    Not in our library10.1056/nejmoa1709030

24. 24.

    Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022;1(11):EVIDoa2200214.

    Not in our library10.1056/evidoa2200214

25. 25.

    Grossmann KF, Othus M, Patel SP, et al. Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma. Cancer Discov. 2022;12(3):644-653.

    Not in our library10.1158/2159-8290.cd-21-1141

26. 26.

    Livingstone E, Zimmer L, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet. 2022;400(10358):1117-1129.

    Not in our library10.1016/s0140-6736(22)01654-3

27. 27.

    NCCN Clinical Practice Guidelines in Oncology Melanoma: Cutaneous. 2024.

    Not in our library

28. 28.

    Weber JS, Khattak MA, Carlino MS, et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. J Clin Oncol. 2024;42(suppl 17):LBA9512.

    Not in our library

29. 29.

    Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19(4):510-520.

    Not in our library10.1016/s1470-2045(18)30106-2

30. 30.

    Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823.

    Not in our library10.1056/nejmoa1708539

31. 31.

    Long GV, Hauschild A, Santinami M, et al. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2024;391(18):1709-1720.

    Not in our library10.1056/nejmoa2404139

32. 32.

    Long GV, Blank CU, Amaria RN, et al. LBA41 Long-term survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Ann Oncol. 2024;35:S1232.

    Not in our library

33. 33.

    Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813-823.

    Not in our library10.1056/nejmoa2211437

34. 34.

    Patel S, Othus M, Prieto V, et al. LBA6 Neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801. Ann Oncol. 2022;33(suppl 7):S1408.

    Not in our library

35. 35.

    Patel S, Othus M, Wright P, et al. LBA48 - Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801. Ann Oncol. 2023;34(suppl 2):S1288.

    Not in our library

36. 36.

    Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391(18):1696-1708.

    Not in our library10.1056/nejmoa2402604

37. 37.

    Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multi-centre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948-960.

    Not in our library10.1016/s1470-2045(19)30151-2

38. 38.

    Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized responsedirected surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178-1188.

    Not in our library10.1038/s41591-022-01851-x

39. 39.

    Hauschild A, Hassel JC, Ziemer M, et al. Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases. J Clin Oncol. 2024;42(suppl 17):LBA9501.

    Not in our library

40. 40.

    Dummer R, Gyorki DE, Hyngstrom J, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021;27(10):1789-1796.

    Not in our library10.1038/s41591-021-01510-7

41. 41.

    Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neo-adjuvant Melanoma Consortium. Lancet Oncol. 2019;20(7):e378-e389.

    Not in our library10.1016/s1470-2045(19)30332-8

42. 42.

    Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29(8):1861-1868.

    Not in our library10.1093/annonc/mdy226

43. 43.

    Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740-4806.

    Not in our library10.1002/cncr.26111

44. 44.

    Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.

    Not in our library10.1056/nejmoa1412082

45. 45.

    Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-1356.

    Not in our library10.1056/nejmoa1709684

46. 46.

    Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.

    Not in our library10.1056/nejmoa1503093

47. 47.

    Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2024.

    Not in our library10.1056/nejmoa2407417

48. 48.

    Long GV, Carlino MS, McNeil C, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35(12):1191-1199.

    Not in our library10.1016/j.annonc.2024.08.2330

49. 49.

    Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.

    Not in our library10.1056/nejmoa1504030

50. 50.
    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma · 2022

    No notice
51. 51.

    Lebbé C, Meyer N, Mortier L, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol. 2019;37(11):867-875.

    Not in our library10.1200/jco.18.01998

52. 52.

    Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24-34.

    Not in our library10.1056/nejmoa2109970

53. 53.

    Long GV, Hodi FS, Lipson EJ, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid. 2023;2(4):EVIDoa2200239.

    Not in our library10.1056/evidoa2200239

54. 54.

    Merck and Eisai provide update on phase 3 trials of KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) in certain patients with advanced melanoma (LEAP-003) and metastatic colorectal cancer (LEAP-017).

    Not in our library

55. 55.

    Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.

    Not in our library10.1016/s0140-6736(15)60898-4

56. 56.

    Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39.

    Not in our library10.1056/nejmoa1412690

57. 57.

    Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876.

    Not in our library10.1056/nejmoa1408868

58. 58.

    Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603-615.

    Not in our library10.1016/s1470-2045(18)30142-6

59. 59.

    Schadendorf D, Dummer R, Flaherty KT, et al. COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Eur J Cancer. 2024;204:114073.

    Not in our library10.1016/j.ejca.2024.114073

60. 60.

    Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOGACRIN EA6134. J Clin Oncol. 2023;41(2):186-197.

    Not in our library10.1200/jco.22.01763

61. 61.

    Ascierto PA, Mandalà M, Ferrucci PF, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol. 2023;41(2):212-221.

    Not in our library10.1200/jco.21.02961

62. 62.

    Ascierto PA, Mandalà M, Ferrucci PF, et al. 1083MO - Brain metastases and survival evaluation in the SECOMBIT trial. Ann Oncol. 2023;34(suppl 2):S653.

    Not in our library

63. 63.

    Robert C, Dutriaux C, Oppong FB, et al. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: the primary analysis of an EORTC randomized phase II study (EBIN). J Clin Oncol. 2024;42(suppl 17):LBA9503.

    Not in our library

64. 64.

    Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611-622.

    Not in our library10.1016/s1470-2045(17)30231-0

65. 65.

    Zimmer L, Apuri S, Eroglu Z, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017;75:47-55.

    Not in our library10.1016/j.ejca.2017.01.009

66. 66.

    VanderWalde A, Bellasea SL, Kendra KL, et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023;29(9):2278-2285.

    Not in our library10.1038/s41591-023-02498-y

67. 67.

    Ascierto PA, Lipson EJ, Dummer R, et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1/programmed death ligand 1 therapy: results from the phase I/IIa RELATIVITY-020 trial. J Clin Oncol. 2023;41(15):2724-2735.

    Not in our library10.1200/jco.22.02072

68. 68.

    Pham JP, Joshua AM, da Silva IP, et al. Chemotherapy in cutaneous melanoma: is there still a role? Curr Oncol Rep. 2023;25(6):609-621.

    Not in our library10.1007/s11912-023-01385-6

69. 69.

    Goldinger SM, Buder-Bakhaya K, Lo SN, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022;162:22-33.

    Not in our library10.1016/j.ejca.2021.11.022

70. 70.

    Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656-2666.

    Not in our library10.1200/jco.21.00612

71. 71.

    Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113-2125.

    Not in our library10.1056/nejmoa2210233

72. 72.

    Monberg TJ, Borch TH, Svane IM, et al. TIL therapy: facts and hopes. Clin Cancer Res. 2023;29(17):3275-3283.

    Not in our library10.1158/1078-0432.ccr-22-2428

73. 73.

    Haanen J. Overview of real-world experience in unmodified tumor-infiltrating lymphocytes therapy. 2024.

    Not in our library

74. 74.

    Arance A, de la Cruz-Merino L, Petrella TM, et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol. 2023;41(1):75-85.

    Not in our library10.1200/jco.22.00221

75. 75.

    Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435-445.

    Not in our library10.1016/s1470-2045(17)30180-8

76. 76.

    Valpione S, Carlino MS, Mangana J, et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study. Eur J Cancer. 2018;91:116-124.

    Not in our library10.1016/j.ejca.2017.12.007

77. 77.

    Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895-1902.

    Not in our library10.1093/annonc/mdy263

78. 78.

    Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340-2366.

    Not in our library10.1093/annonc/mdx310

79. 79.

    Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139-144.

    Not in our library10.1086/321805

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.